Bristol Myers: Orencia Improves Survival in Hospitalized Covid-19 Patients
June 02 2022 - 11:50AM
Dow Jones News
By Colin Kellaher
Bristol Myers Squibb Co. on Thursday said its blockbuster
arthritis drug Orencia helped improve survival in a Phase 3 study
in people hospitalized with Covid-19.
The New York biopharmaceutical company said treatment with
Orencia versus placebo showed a strong but not statistically
significant improvement in the primary endpoint of time to recovery
as measured by day of hospital discharge in the study sponsored by
the National Institutes of Health.
The study evaluated the safety and efficacy of a single dose of
immune modulators, including Orencia, when given with standard of
care to determine if modulating the immune system's response could
speed recovery and reduce death in adults hospitalized with
moderate to severe Covid-19.
Bristol Myers said analyses of the study's secondary endpoints,
which included mortality and clinical status, showed Orencia
reduced participants' risk of death and improved their clinical
status at 28 days after entering the study when compared with
placebo.
The company said Orencia's safety profile remained consistent,
with no new safety signals reported in the study.
Bristol Myers said that given the positive study findings, it
plans to discuss the data and potential next steps with the U.S.
Food and Drug Administration.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
June 02, 2022 11:35 ET (15:35 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Aug 2024 to Sep 2024
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Sep 2023 to Sep 2024